Allergen-induced bronchial eosinophilia in guinea-pigs is inhibited by both pre- and post-induction cyclosporin-A treatments

International Journal of Immunopharmacology

Volumn 22, Issue 7, 2000, Pages 515-522

  Ezeamuzie, Charles I ^a   Nwankwoala, Reginald N P ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b UNIVERSITY OF PORT HARCOURT   (Nigeria)

Author keywords

Bronchial lavage; Cyclosporin A; Eosinophil; Guinea pig

Indexed keywords

ALLERGEN; CYCLOSPORIN A; OVALBUMIN;

AEROSOL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; EOSINOPHILIA; GUINEA PIG; LOEFFLER PNEUMONIA; LUNG LAVAGE; MALE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ADMINISTRATION, INHALATION; AEROSOLS; ALLERGENS; ANIMALS; BRONCHI; BRONCHOALVEOLAR LAVAGE FLUID; CELL MOVEMENT; CYCLOSPORINE; EOSINOPHILIA; GUINEA PIGS; IMMUNOSUPPRESSIVE AGENTS; MALE; OVALBUMIN;

EID: 0034237372     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(00)00015-1     Document Type: Article

References (17)

1. Alexander A.G., Barnes N.C., Kay A.B. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet. 339:1992;324-328.
2. Barnes P.J. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J. Allergy Clin. Immunol. 83:1989;1013-1026.
3. Baumann G. Molecular mechanisms of immunosuppressive agents. Transplant. Proc. 24:(4):1992;4-7. Suppl 2.
4. Borel J.F., Feurer C., Gubler H.U., Stahelin A. Biological effects of cyclosporin-A: a new anti-lymphocyte agent. Agents & Actions. 6:1976;468-475.
5. Elwood Y., Lotvall J.O., Barnes P.J., Chung K.F. Effect of dexamethasone and cyclosporin A on the allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats. Am. Rev. Respir. Dis. 145:1992;1289-1294.
6. Ezeamuzie C.I., Assem E.S.K. Anti-allergic properties of cyclosporin-A: inhibition of mediator release from human basophils and rat basophilic leukemia cells (RBL-2H3). Immunopharmacol. 20:1990;31-43.
7. Fakuda T., Akutsu I., Motojima S., Makino S. Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. Int. Arch. Allergy Appl. Immunol. 94:1991;259-261.
8. Feutren G. Clinical experience with sandimmune (CSA) in autoimmune diseases. Transplant Proc. 24:(Suppl. 2):1992;55-60.
9. Flavahan N.A., Slifman N.R., Gleich G.J., Vanhoutte P.M. Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscles. Am. Rev. Respir. Dis. 138:1988;685-688.
10. Frigas E., Gleich G.J. The eosinophils and the pathophysiology of asthma. J. Allergy Clin. Immunol. 77:1986;527-537.
11. Gleich G.J., Adolphson C.R. The eosinophil leukocyte: structure and function. Adv. Immunol. 39:1986;177-253.
12. Meng Q., Ying S., Corrigan C.J., Wakelin M., Assoufi B., Moqbel R., Kay A.B. Effects of rapamycin, cyclosporin-A and dexamethasone on IL-5-induced eosinophil degranulation and prolonged survival. Allergy. 52:1997;1095-1101.
13. Norris A.A., Jackson D.M., Eady R.P. Protective effects of cyclophosphamide, cyclosporin A and FK 506 against antigen-induced lung eosinophilia in guinea pigs. Clin. Exp. Immunol. 89:1992;347-350.
14. Simon H.U., Blaser K. Inhibition of programmed death: a key pathogenic event in eosinophilia. Immunol. Today. 16:1995;53-55.
15. Teixeira M.M., Williams T.J., Hellewell P.G. Mechanisms and pharmacological manipulation of eosinophil accumulation in vivo. TIPS. 16:1995;418-423.
16. 2 release from human lung mast cells by cyclosporin A. Int. Arch. Allergy Appl. Immunol. 88:1989;253-255.
17. Tugwell P., Bombardier C., Gent M., Bennett M., Bensen W.G., Carette S., Chalmers A., Esdaile J.M., Klinkhoff A.V., Kraag G.R., Ludwin D., Roberts R.S. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet. 335:1990;1051-1055.